Suzano S.A. (SUZ)
Every figure this model derived for SUZ, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.
The figures, and where each came from
This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.
| Figure | Value | XBRL tag | As at |
|---|---|---|---|
| capex | 4,578,826,000 | PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
2025-12-31 |
| cash | 15,179,753,000 | CashAndCashEquivalents |
2025-12-31 |
| current assets | 43,867,069,000 | CurrentAssets |
2025-12-31 |
| current liabilities | 13,772,871,000 | CurrentLiabilities |
2025-12-31 |
| equity | 43,812,045,000 | EquityAttributableToOwnersOfParent |
2025-12-31 |
| interest expense | 6,883,755,000 | FinanceCosts |
2025-12-31 |
| ocf | 18,152,175,000 | CashFlowsFromUsedInOperatingActivities |
2025-12-31 |
| revenue | 50,115,679,000 | RevenueFromContractsWithCustomers |
2025-12-31 |
| sbc | 0 | AdjustmentsForSharebasedPayments |
2021-12-31 |
The ratios
The figures themselves rather than their scores — what somebody looking up SUZ on one particular measure came for.
| Ratio | Value |
|---|---|
| cash operating margin | 43.79 |
| current ratio | 3.19 |
| current ratio reported | 3.19 |
| dilution pct | -1.98 |
| ebit cagr | -12.52 |
| ebit yoy | -32.13 |
| fcf margin | 27.08 |
| growth cv | 1.53 |
| interest cover | 1.55 |
| net debt ebitda | 3.94 |
| operating margin | 21.25 |
| owner earnings margin | 27.08 |
| revenue growth | 5.72 |
| revenue growth per share | 7.86 |
| roic | 6.45 |
| rule of 40 | 26.97 |
| sbc pct revenue | 0.0 |
Everything else this filing tags
283 more elements from SUZ's own XBRL that this model has no measure for, newest reading each, largest first. Nothing here is converted, added up or renamed — it is the filing's own element names and the filing's own numbers.
| Element | Newest | As of | Periods | Unit |
|---|---|---|---|---|
NumberOfSharesOutstanding | 1,324,117,615,000 | 2023-12-31 | 15 | shares |
Assets | 167,935,519,000 | 2025-12-31 | 37 | BRL |
EquityAndLiabilities | 167,935,519,000 | 2025-12-31 | 36 | BRL |
NoncurrentAssets | 124,068,450,000 | 2025-12-31 | 36 | BRL |
Liabilities | 123,983,346,000 | 2025-12-31 | 37 | BRL |
NoncurrentLiabilities | 110,210,475,000 | 2025-12-31 | 36 | BRL |
Borrowings | 94,801,257,000 | 2025-12-31 | 54 | BRL |
LongtermBorrowings | 91,796,352,000 | 2025-12-31 | 36 | BRL |
FinancialLiabilities | 74,082,444,000 | 2019-12-31 | 4 | BRL |
PropertyPlantAndEquipment | 64,296,187,000 | 2025-12-31 | 47 | BRL |
Equity | 43,952,173,000 | 2025-12-31 | 72 | BRL |
FinancialLiabilitiesAtFairValue | 43,501,845,000 | 2018-12-31 | 2 | BRL |
CostOfSales | 33,889,504,000 | 2025-12-31 | 60 | BRL |
FinancialAssetsAtFairValue | 28,517,010,000 | 2018-12-31 | 2 | BRL |
NoncurrentBiologicalAssets | 26,097,164,000 | 2025-12-31 | 54 | BRL |
IssuedCapital | 24,235,546,000 | 2025-12-31 | 33 | BRL |
ProceedsFromBorrowingsClassifiedAsFinancingActivities | 23,871,760,000 | 2025-12-31 | 46 | BRL |
CashFlowsFromUsedInOperations | 22,881,170,000 | 2025-12-31 | 43 | BRL |
PropertyPlantAndEquipmentPledgedAsSecurity | 21,569,807,000 | 2025-12-31 | 36 | BRL |
CurrentFinancialAssets | 21,098,565,000 | 2018-12-31 | 2 | BRL |
AccountingProfit | 20,411,174,000 | 2025-12-31 | 43 | BRL |
ProfitLossBeforeTax | 20,411,174,000 | 2025-12-31 | 60 | BRL |
StatutoryReserve | 20,118,234,000 | 2025-12-31 | 25 | BRL |
GrossProfit | 16,226,175,000 | 2025-12-31 | 60 | BRL |
ContractualCapitalCommitments | 14,606,380,000 | 2023-12-31 | 11 | BRL |
FinancialAssets | 14,298,290,000 | 2019-12-31 | 4 | BRL |
ProfitLoss | 13,437,687,000 | 2025-12-31 | 60 | BRL |
ProfitLossAttributableToOwnersOfParent | 13,408,189,000 | 2025-12-31 | 59 | BRL |
RetainedEarnings | 13,400,962,000 | 2025-09-30 | 16 | BRL |
ComprehensiveIncome | 13,093,769,000 | 2025-12-31 | 60 | BRL |
ComprehensiveIncomeAttributableToOwnersOfParent | 13,064,271,000 | 2025-12-31 | 60 | BRL |
IntangibleAssetsAndGoodwill | 12,970,692,000 | 2025-12-31 | 34 | BRL |
DepreciationAndAmortisationExpense | 11,297,258,000 | 2025-12-31 | 46 | BRL |
AdjustmentsForDepreciationAndAmortisationExpense | 10,913,290,000 | 2025-12-31 | 46 | BRL |
GainLossOnHedgeIneffectivenessRecognisedInProfitOrLoss | -10,835,114,000 | 2020-06-30 | 7 | BRL |
ProfitLossFromOperatingActivities | 10,649,009,000 | 2025-12-31 | 60 | BRL |
NetDebt | 10,251,491,000 | 2018-12-31 | 2 | BRL |
GainsOnChangeInFairValueOfDerivatives | 10,033,761,000 | 2025-12-31 | 43 | BRL |
IssuedCapitalOrdinaryShares | 10,000,000,000 | 2024-04-25 | 2 | BRL |
BalancesWithBanks | 9,881,326,000 | 2025-12-31 | 30 | BRL |
CashFlowsFromUsedInInvestingActivities | -9,832,727,000 | 2025-12-31 | 46 | BRL |
FinanceIncomeCost | 9,762,165,000 | 2025-12-31 | 47 | BRL |
ExpenseByNature | 8,443,141,000 | 2018-12-31 | 3 | BRL |
Inventories | 8,155,847,000 | 2025-12-31 | 36 | BRL |
NoncurrentDerivativeFinancialLiabilities | 8,136,320,000 | 2025-12-31 | 36 | BRL |
NoncurrentDerivativeFinancialAssets | 8,014,683,000 | 2025-12-31 | 36 | BRL |
AdditionsFromPurchasesBiologicalAssets | 7,913,483,000 | 2025-12-31 | 36 | BRL |
PurchaseOfBiologicalAssets | 7,913,483,000 | 2025-12-31 | 46 | BRL |
AdjustmentsForUnrealisedForeignExchangeLossesGains | -7,550,610,000 | 2025-12-31 | 46 | BRL |
GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss | 7,550,610,000 | 2025-12-31 | 61 | BRL |
GainsLossesOnChangeInFairValueOfDerivatives | 7,328,684,000 | 2025-12-31 | 58 | BRL |
IncomeTaxExpenseContinuingOperations | -6,973,487,000 | 2025-12-31 | 46 | BRL |
TaxExpenseIncomeAtApplicableTaxRate | -6,939,799,000 | 2025-12-31 | 43 | BRL |
LeaseLiabilities | 6,929,890,000 | 2025-12-31 | 50 | BRL |
DeferredTaxAssets | 6,752,162,000 | 2023-12-31 | 20 | BRL |
TradeAndOtherCurrentReceivables | 6,560,607,000 | 2025-12-31 | 18 | BRL |
IncreaseDecreaseInCashAndCashEquivalents | 6,499,821,000 | 2025-12-31 | 46 | BRL |
CurrentTradeReceivables | 6,488,192,000 | 2023-06-30 | 18 | BRL |
AdjustmentsForDeferredTaxExpense | 6,455,108,000 | 2025-12-31 | 55 | BRL |
DeferredTaxLiabilities | 6,218,326,000 | 2023-12-31 | 20 | BRL |
NoncurrentLeaseLiabilities | 6,072,080,000 | 2025-12-31 | 33 | BRL |
AdjustmentsForInterestExpense | 5,953,778,000 | 2025-12-31 | 46 | BRL |
BorrowingCostsIncurred | 5,953,778,000 | 2025-12-31 | 32 | BRL |
InterestPaidClassifiedAsOperatingActivities | 5,817,907,000 | 2025-12-31 | 46 | BRL |
InterestExpenseOnBorrowings | 5,679,047,000 | 2025-12-31 | 46 | BRL |
DecreaseDueToHarvestBiologicalAssets | 5,352,271,000 | 2025-12-31 | 36 | BRL |
RightofuseAssets | 5,331,789,000 | 2025-12-31 | 49 | BRL |
TradeAndOtherCurrentPayablesToTradeSuppliers | 5,141,386,000 | 2025-12-31 | 36 | BRL |
IncreaseDecreaseThroughTransfersAndOtherChangesEquity | 5,000,000,000 | 2025-12-10 | 2 | BRL |
DepreciationPropertyPlantAndEquipment | 4,845,176,000 | 2025-12-31 | 20 | BRL |
IntangibleAssetsOtherThanGoodwill | 4,778,353,000 | 2025-12-31 | 54 | BRL |
DeferredTaxExpenseIncome | -4,733,439,000 | 2025-12-31 | 43 | BRL |
ProceedsFromIssueOfBondsNotesAndDebentures | 4,681,100,000 | 2018-12-31 | 1 | BRL |
NotesAndDebenturesIssued | 4,663,453,000 | 2018-12-31 | 1 | BRL |
NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued | 4,662,156,000 | 2018-12-31 | 1 | BRL |
AcquisitionsThroughBusinessCombinationsBiologicalAssets | 4,579,526,000 | 2019-12-31 | 3 | BRL |
AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment | 4,578,826,000 | 2025-12-31 | 20 | BRL |
IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset | -3,941,212,000 | 2025-12-31 | 34 | BRL |
OtherProvisions | 3,447,076,000 | 2021-06-30 | 10 | BRL |
SellingExpense | 3,312,740,000 | 2025-12-31 | 60 | BRL |
NoncurrentProvisions | 3,271,679,000 | 2021-06-30 | 11 | BRL |
ShorttermInvestmentsClassifiedAsCashEquivalents | 3,235,687,000 | 2018-12-31 | 2 | BRL |
IssueOfEquity | 3,027,528,000 | 2019-12-31 | 4 | BRL |
CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings | 3,004,905,000 | 2025-12-31 | 36 | BRL |
IncreaseDecreaseThroughTransfersAndOtherChangesOtherProvisions | 2,902,352,000 | 2019-12-31 | 1 | BRL |
LongtermLegalProceedingsProvision | 2,801,738,000 | 2025-12-31 | 26 | BRL |
GeneralAndAdministrativeExpense | 2,790,154,000 | 2025-12-31 | 60 | BRL |
AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives | -2,735,196,000 | 2018-12-31 | 3 | BRL |
LossesOnChangeInFairValueOfDerivatives | 2,705,077,000 | 2025-12-31 | 43 | BRL |
PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod | 2,595,974,000 | 2024-12-31 | 13 | BRL |
PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod | 2,595,974,000 | 2024-12-31 | 5 | BRL |
CurrentTaxAssets | 2,105,201,000 | 2023-06-30 | 18 | BRL |
CashFlowsFromUsedInFinancingActivities | -1,819,627,000 | 2025-12-31 | 46 | BRL |
FinanceIncome | 1,766,626,000 | 2025-12-31 | 60 | BRL |
AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment | 1,702,768,000 | 2024-12-31 | 15 | BRL |
AdjustmentsForDecreaseIncreaseInTradeAccountReceivable | 1,586,613,000 | 2025-12-31 | 46 | BRL |
InterestIncomeOnCashAndCashEquivalents | 1,584,056,000 | 2025-12-31 | 40 | BRL |
CurrentDerivativeFinancialAssets | 1,556,978,000 | 2025-12-31 | 36 | BRL |
CurrentTaxAssetsCurrent | 1,546,287,000 | 2025-12-31 | 36 | BRL |
CurrentInterestPayable | 1,525,436,000 | 2025-12-31 | 34 | BRL |
InterestPayable | 1,525,436,000 | 2025-12-31 | 34 | BRL |
GainsLossesOnFairValueAdjustmentBiologicalAssets | -1,516,458,000 | 2025-12-31 | 52 | BRL |
IncreaseDecreaseInFairValueMeasurementAssets | -1,516,458,000 | 2025-12-31 | 9 | BRL |
TreasuryShares | 1,511,146,000 | 2025-12-31 | 50 | BRL |
DeferredTaxLiabilityAsset | 1,504,014,000 | 2025-12-31 | 51 | BRL |
NetDeferredTaxAssets | 1,504,014,000 | 2025-12-31 | 36 | BRL |
SpareParts | 1,491,820,000 | 2025-12-31 | 36 | BRL |
PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities | 1,447,973,000 | 2025-12-31 | 40 | BRL |
NoncurrentFinancialAssetsAtFairValueThroughOtherComprehensiveIncome | 1,427,438,000 | 2025-03-31 | 6 | BRL |
DividendsPayable | 1,393,121,000 | 2025-12-31 | 36 | BRL |
RawMaterials | 1,373,217,000 | 2021-06-30 | 10 | BRL |
AdjustedWeightedAverageShares | 1,239,714,000 | 2025-12-31 | 46 | shares |
WeightedAverageShares | 1,236,702,000 | 2025-12-31 | 46 | shares |
AreaOfLandUsedForAgriculture | 1,228,834,000 | 2025-12-31 | 31 | ha |
InterestReceivedClassifiedAsOperatingActivities | 1,213,789,000 | 2025-12-31 | 37 | BRL |
CurrentDerivativeFinancialLiabilities | 1,205,029,000 | 2025-12-31 | 36 | BRL |
InvestmentAccountedForUsingEquityMethod | 1,194,877,000 | 2025-12-31 | 36 | BRL |
GainsLossesOnFairValueAdjustmentAttributableToPriceChangesBiologicalAssets | -1,191,013,000 | 2025-12-31 | 28 | BRL |
AdditionsToRightofuseAssets | 1,092,768,000 | 2020-12-31 | 5 | BRL |
IncreaseDecreaseThroughAcquisitionOfSubsidiary | 1,060,718,000 | 2023-12-31 | 6 | BRL |
IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset | 1,034,842,000 | 2019-12-31 | 3 | BRL |
AmortisationIntangibleAssetsOtherThanGoodwill | 1,011,088,000 | 2025-12-31 | 36 | BRL |
DividendPayables | 1,000,000,000 | 2022-01-07 | 2 | BRL |
CurrentTaxAssetsNoncurrent | 945,699,000 | 2025-12-31 | 36 | BRL |
OtherOperatingIncomeExpense | 934,940,000 | 2025-12-31 | 60 | BRL |
FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome | 901,181,000 | 2025-12-31 | 33 | BRL |
OtherReserves | 888,669,000 | 2025-12-31 | 36 | BRL |
OtherCurrentAssets | 858,005,000 | 2025-12-31 | 36 | BRL |
CurrentLeaseLiabilities | 857,810,000 | 2025-12-31 | 33 | BRL |
NoncurrentRecognisedLiabilitiesDefinedBenefitPlan | 741,143,000 | 2025-12-31 | 26 | BRL |
LiabilityAssetOfDefinedBenefitPlans | 741,143,000 | 2025-12-31 | 27 | BRL |
CurrentInvestments | 656,738,000 | 2024-06-30 | 2 | BRL |
InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod | 656,738,000 | 2024-06-30 | 2 | BRL |
DividendsRecognisedAsDistributionsToOwnersOfParent | 600,000,000 | 2019-04-18 | 4 | BRL |
OtherFinanceCost | 524,843,000 | 2025-12-31 | 46 | BRL |
AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment | -475,267,000 | 2025-12-31 | 46 | BRL |
InterestExpenseOnLeaseLiabilities | 467,879,000 | 2025-12-31 | 40 | BRL |
OtherCurrentNonfinancialLiabilities | 429,532,000 | 2025-12-31 | 36 | BRL |
DisposalsPropertyPlantAndEquipment | 426,152,000 | 2025-12-31 | 20 | BRL |
LongtermDeposits | 418,301,000 | 2025-12-31 | 36 | BRL |
CurrentTaxExpenseIncome | -409,896,000 | 2025-12-31 | 43 | BRL |
ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod | -409,212,000 | 2025-12-31 | 60 | BRL |
GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss | 392,018,000 | 2019-12-31 | 6 | BRL |
AcquisitionsThroughBusinessCombinationsOtherProvisions | 389,593,000 | 2019-12-31 | 3 | BRL |
GainsLossesOnDisposalsOfPropertyPlantAndEquipment | -386,396,000 | 2025-12-31 | 19 | BRL |
DepreciationRightofuseAssets | 383,968,000 | 2025-12-31 | 40 | BRL |
AdditionsOtherThanThroughBusinessCombinationsBiologicalAssets | 366,785,000 | 2024-12-31 | 7 | BRL |
OtherComprehensiveIncome | -343,918,000 | 2025-12-31 | 40 | BRL |
EffectOfExchangeRateChangesOnCashAndCashEquivalents | -338,886,000 | 2025-12-31 | 46 | BRL |
NoncurrentProvisionsForEmployeeBenefits | 332,322,000 | 2025-12-31 | 36 | BRL |
IncomeTaxesPaidClassifiedAsOperatingActivities | 327,282,000 | 2018-12-31 | 3 | BRL |
GainsLossesOnFairValueAdjustmentAttributableToPhysicalChangesBiologicalAssets | -325,445,000 | 2025-12-31 | 28 | BRL |
IncomeTaxesPaidRefundClassifiedAsOperatingActivities | 289,548,000 | 2025-12-31 | 43 | BRL |
EstimatedFinancialEffectOfContingentLiabilities | 279,934,000 | 2019-12-31 | 1 | BRL |
InterestCostsCapitalised | 274,731,000 | 2025-12-31 | 26 | BRL |
AdjustmentsForFinanceCosts | -274,731,000 | 2025-12-31 | 21 | BRL |
InvestmentsInSubsidiariesJointVenturesAndAssociates | 264,312,000 | 2025-12-31 | 34 | BRL |
BorrowingCostsRecognisedAsExpense | 260,289,000 | 2021-12-31 | 7 | BRL |
AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables | 259,705,000 | 2025-12-31 | 46 | BRL |
NumberOfSharesIssued | 255,437,439 | 2019-01-31 | 1 | shares |
CurrentTaxLiabilitiesCurrent | 240,010,000 | 2025-12-31 | 36 | BRL |
OtherComprehensiveIncomeBeforeTaxGainsLossesFromInvestmentsInEquityInstruments | -220,314,000 | 2025-12-31 | 43 | BRL |
AdjustmentsForIncreaseDecreaseInOtherOperatingPayables | -218,901,000 | 2025-12-31 | 46 | BRL |
AdjustmentsForDecreaseIncreaseInInventories | -216,357,000 | 2025-12-31 | 46 | BRL |
OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax | -214,857,000 | 2025-12-31 | 57 | BRL |
FinanceCostsPaidClassifiedAsOperatingActivities | 205,409,000 | 2025-09-30 | 27 | BRL |
DividendsPaidClassifiedAsFinancingActivities | 192,532,000 | 2023-12-31 | 21 | BRL |
PaymentsToAcquireOrRedeemEntitysShares | 191,918,000 | 2025-12-31 | 28 | BRL |
AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill | 189,655,000 | 2023-06-30 | 3 | BRL |
RevaluationIncreaseDecreaseIntangibleAssetsOtherThanGoodwill | 189,655,000 | 2023-12-31 | 4 | BRL |
OtherNoncurrentAssets | 187,102,000 | 2025-12-31 | 36 | BRL |
OtherFinanceIncome | 182,570,000 | 2025-12-31 | 46 | BRL |
OtherNoncurrentNonfinancialLiabilities | 178,684,000 | 2025-12-31 | 36 | BRL |
IncreaseDecreaseThroughTransfersAndOtherChangesBiologicalAssets | -170,925,000 | 2025-12-31 | 36 | BRL |
KeyManagementPersonnelCompensation | 157,826,000 | 2025-12-31 | 46 | BRL |
OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans | -147,640,000 | 2019-12-31 | 6 | BRL |
AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories | 141,635,000 | 2025-12-31 | 45 | BRL |
NoncontrollingInterests | 140,128,000 | 2025-12-31 | 35 | BRL |
NoncurrentInterestPayable | 136,799,000 | 2019-12-31 | 3 | BRL |
CurrentAdvances | 132,408,000 | 2025-12-31 | 36 | BRL |
OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossBeforeTax | -129,061,000 | 2025-12-31 | 50 | BRL |
ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets | 122,729,000 | 2025-12-31 | 38 | BRL |
InterestExpenseOnOtherFinancialLiabilities | 120,991,000 | 2018-12-31 | 3 | BRL |
AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeAndOtherReceivables | 119,417,000 | 2025-12-31 | 46 | BRL |
RevenueFromRenderingOfServicesRelatedPartyTransactions | 118,040,000 | 2018-12-31 | 2 | BRL |
WorkInProgress | 113,212,000 | 2025-12-31 | 36 | BRL |
DisposalsBiologicalAssets | 107,815,000 | 2025-12-31 | 36 | BRL |
GainsLossesOnExchangeDifferencesOnTranslationNetOfTax | -105,405,000 | 2025-12-31 | 60 | BRL |
OtherAdjustmentsForNoncashItems | 92,622,000 | 2025-12-31 | 35 | BRL |
KeyManagementPersonnelCompensationSharebasedPayment | 92,114,000 | 2025-12-31 | 46 | BRL |
AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities | -91,499,000 | 2025-12-31 | 46 | BRL |
ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss | 88,871,000 | 2025-12-31 | 4 | BRL |
AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill | 82,492,000 | 2025-12-31 | 36 | BRL |
PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities | 82,492,000 | 2025-12-31 | 46 | BRL |
AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination | 82,426,000 | 2025-12-31 | 8 | BRL |
CapitalReserve | 80,742,000 | 2025-12-31 | 36 | BRL |
IncreaseDecreaseThroughTransfersAndOtherChangesIntangibleAssetsOtherThanGoodwill | 79,674,000 | 2023-12-31 | 23 | BRL |
NewProvisionsOtherProvisions | 78,620,000 | 2018-12-31 | 2 | BRL |
WritedownsReversalsOfInventories | 78,203,000 | 2025-12-31 | 6 | BRL |
AmountsReceivableRelatedPartyTransactions | 78,139,000 | 2023-06-30 | 8 | BRL |
InterestExpenseIncomeNetDefinedBenefitLiabilityAsset | 77,348,000 | 2025-12-31 | 18 | BRL |
CurrentAdvancesToSuppliers | 76,818,000 | 2025-12-31 | 36 | BRL |
IncreaseDecreaseThroughLossOfControlOfSubsidiaryDeferredTaxLiabilityAsset | -76,753,000 | 2025-09-30 | 4 | BRL |
AdjustmentsForIncreaseInOtherProvisionsArisingFromPassageOfTime | 75,791,000 | 2018-12-31 | 3 | BRL |
NoncurrentAdvances | 74,715,000 | 2025-12-31 | 26 | BRL |
TaxEffectOfForeignTaxRates | 72,890,000 | 2020-12-31 | 5 | BRL |
AllowanceAccountForCreditLossesOfFinancialAssets | 71,183,000 | 2024-06-30 | 9 | BRL |
UnusedProvisionReversedOtherProvisions | 68,635,000 | 2020-06-30 | 6 | BRL |
OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome | 68,623,000 | 2020-12-31 | 6 | BRL |
KeyManagementPersonnelCompensationShorttermEmployeeBenefits | 65,712,000 | 2025-12-31 | 46 | BRL |
ProceedsFromOtherLongtermAssetsClassifiedAsInvestingActivities | 61,887,000 | 2020-06-30 | 8 | BRL |
ExpenseOfRestructuringActivities | 59,725,000 | 2025-12-31 | 6 | BRL |
ProvisionUsedOtherProvisions | 52,693,000 | 2020-06-30 | 4 | BRL |
PaymentsFromPlanNetDefinedBenefitLiabilityAsset | 52,390,000 | 2025-12-31 | 18 | BRL |
IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome | -50,198,000 | 2019-12-31 | 6 | BRL |
InvestmentsInSubsidiaries | 46,922,000 | 2018-12-31 | 1 | BRL |
IncreaseDecreaseThroughSharebasedPaymentTransactions | 45,642,000 | 2025-12-31 | 44 | BRL |
AdjustmentsForImpairmentLossRecognisedInProfitOrLossGoodwill | 45,435,000 | 2020-12-31 | 1 | BRL |
AdditionalProvisionsOtherProvisions | 42,233,000 | 2020-06-30 | 4 | BRL |
UtilisationAllowanceAccountForCreditLossesOfFinancialAssets | 38,584,000 | 2024-06-30 | 6 | BRL |
ShareIssueRelatedCost | 33,735,000 | 2021-06-30 | 2 | BRL |
DividendsRecognisedAsDistributionsToOwnersOfParentRelatingToPriorYears | 29,976,000 | 2018-12-31 | 1 | BRL |
ComprehensiveIncomeAttributableToNoncontrollingInterests | 29,498,000 | 2025-12-31 | 57 | BRL |
ProfitLossAttributableToNoncontrollingInterests | 29,498,000 | 2025-12-31 | 57 | BRL |
Goodwill | 29,384,000 | 2025-12-31 | 35 | BRL |
ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax | 23,656,000 | 2025-12-31 | 26 | BRL |
AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment | 23,395,000 | 2021-06-30 | 10 | BRL |
IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions | 22,559,000 | 2020-06-30 | 4 | BRL |
CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities | 21,979,000 | 2025-12-31 | 37 | BRL |
CancellationOfTreasuryShares | 17,107,000 | 2017-12-31 | 1 | BRL |
AdditionalAllowanceRecognisedInProfitOrLossAllowanceAccountForCreditLossesOfFinancialAssets | 15,132,000 | 2024-06-30 | 6 | BRL |
AdjustmentsForIncomeTaxExpense | 15,108,000 | 2023-12-31 | 10 | BRL |
IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions | 13,703,000 | 2018-12-31 | 2 | BRL |
AmountsPayableRelatedPartyTransactions | 13,161,000 | 2023-06-30 | 6 | BRL |
AmountOfReclassificationsOrChangesInPresentation | 12,870,000 | 2018-12-31 | 1 | BRL |
NetDeferredTaxLiabilities | 12,596,000 | 2024-12-31 | 27 | BRL |
ImpairmentLossRecognisedInProfitOrLossBiologicalAssets | 10,903,000 | 2018-12-31 | 2 | BRL |
OtherInflowsOutflowsOfCashClassifiedAsFinancingActivities | 10,191,000 | 2019-12-31 | 4 | BRL |
DividendsReceivedClassifiedAsInvestingActivities | 8,835,000 | 2025-12-31 | 25 | BRL |
ProceedsFromSaleOrIssueOfTreasuryShares | 8,514,000 | 2018-12-31 | 3 | BRL |
AdjustmentsForUndistributedProfitsOfInvestmentsAccountedForUsingEquityMethod | 7,576,000 | 2018-12-31 | 3 | BRL |
AdjustmentsForIncreaseDecreaseInTradeAccountPayable | 6,630,000 | 2025-12-31 | 46 | BRL |
PurchaseOfInterestsInAssociates | 6,516,000 | 2021-12-31 | 9 | BRL |
GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset | 6,026,000 | 2025-12-31 | 14 | BRL |
DividendsPaid | 5,628,000 | 2025-12-31 | 12 | BRL |
ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment | 5,507,000 | 2018-12-31 | 2 | BRL |
IncreaseDecreaseThroughTreasuryShareTransactions | -5,157,000 | 2025-12-31 | 6 | BRL |
IntangibleAssetsWithIndefiniteUsefulLife | 4,018,000 | 2023-06-30 | 4 | BRL |
ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed | 3,191,000 | 2025-12-31 | 33 | BRL |
DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill | 3,015,000 | 2025-12-31 | 11 | BRL |
DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares | 3,012,000 | 2025-12-31 | 32 | shares |
IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill | 2,930,000 | 2019-12-31 | 6 | BRL |
ReversalOfImpairmentLossRecognisedInProfitOrLossBiologicalAssets | 2,846,000 | 2017-12-31 | 1 | BRL |
ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillNotBeReclassifiedToProfitOrLossBeforeTax | 2,749,000 | 2019-12-31 | 1 | BRL |
CurrentServiceCostDefinedBenefitPlans | 1,939,000 | 2025-12-31 | 18 | BRL |
TradeAndOtherCurrentPayablesToRelatedParties | 1,804,000 | 2018-12-31 | 2 | BRL |
CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued | 1,297,000 | 2018-12-31 | 1 | BRL |
IncreaseDecreaseThroughNetExchangeDifferencesAllowanceAccountForCreditLossesOfFinancialAssets | -982,000 | 2018-12-31 | 2 | BRL |
IncomeTaxRelatingToShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillNotBeReclassifiedToProfitOrLoss | 869,000 | 2020-06-30 | 5 | BRL |
IncomeTaxRelatingToInvestmentsInEquityInstrumentsOfOtherComprehensiveIncome | -629,000 | 2025-12-31 | 43 | BRL |
IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset | 577,000 | 2022-12-31 | 1 | BRL |
ReversalAllowanceAccountForCreditLossesOfFinancialAssets | 418,000 | 2024-06-30 | 6 | BRL |
OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities | -286,000 | 2019-12-31 | 4 | BRL |
IncomeFromReimbursementsUnderInsurancePolicies | 93,000 | 2022-06-30 | 9 | BRL |
ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed | 56,000 | 2025-12-31 | 33 | BRL |
ParValuePerShare | 238 | 2024-06-24 | 2 | BRL/shares |
ParValuePerShare | 40 | 2024-08-30 | 3 | EUR/shares |
BasicEarningsLossPerShare | 11 | 2025-12-31 | 61 | BRL/shares |
DilutedEarningsLossPerShare | 11 | 2025-12-31 | 61 | BRL/shares |
PercentageOfEntitysRevenue | 1 | 2018-12-31 | 3 | pure |
ProportionOfOwnershipInterestInSubsidiary | 1 | 2025-12-31 | 14 | pure |
DividendsPaidOrdinarySharesPerShare | 1 | 2022-04-26 | 1 | BRL/shares |
AverageEffectiveTaxRate | 0 | 2024-06-30 | 25 | pure |
ApplicableTaxRate | 0 | 2023-06-30 | 19 | pure |
ProportionOfOwnershipInterestInAssociate | 0 | 2021-12-31 | 2 | pure |
DescriptionOfDiscountRatesUsedInCurrentEstimateOfValueInUse | 0 | 2025-12-31 | 9 | pure |
DiscountRateUsedInCurrentMeasurementOfFairValueLessCostsOfDisposal | 0 | 2023-06-30 | 17 | pure |
DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections | 0 | 2025-12-31 | 7 | pure |
BiologicalAssetsPledgedAsSecurityForLiabilities | 0 | 2023-06-30 | 14 | BRL |
DividendsPaidClassifiedAsOperatingActivities | 0 | 2020-12-31 | 5 | BRL |
InventoriesPledgedAsSecurityForLiabilities | 0 | 2023-06-30 | 16 | BRL |
PurchaseOfTreasuryShares | 0 | 2020-06-30 | 3 | BRL |
SaleOrIssueOfTreasuryShares | 0 | 2020-06-30 | 4 | BRL |
What to be careful about
What this model itself distrusts about SUZ's figures. Written by the derivation as it ran, not added afterwards.
- no current stock compensation tagged (last tagged 2021-12-31); treated as zero, so owner earnings are overstated
- reports in BRL while its share price is quoted in USD, and no exchange rate could be used (no rate for USD to BRL that is less than 30 days old, and this is not a refresh). Every multiple would pair one currency with another, so none of them is a ratio — set `market_cap` in overrides.yaml in BRL to score it
- forward EPS growth -67.6% is analyst consensus, not a filing: consensus 2027 EPS 1.12 against trailing 10.63, over 2 year(s), from 1 analysts (taken 2026-09-18)
- valuation DROPPED from the total: only 0 of 2 inputs could be computed (ev sales, ev owner earnings not tagged), so the score is not meaningful. Its weight is spread over the other dimensions
- durability rests on 3 of 4 inputs; not tagged: contracted coverage